Jean Henslee-Downey Selected Research

tucotuzumab celmoleukin

1/2013

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean Henslee-Downey Research Topics

Disease

2	Neoplasms (Cancer) 01/2013 - 06/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2006 - 02/2005
1	Hypotension (Low Blood Pressure) 01/2013
1	Hypophosphatemia 01/2013
1	Bronchiolitis Obliterans Syndrome 11/2005
1	Leukemia 02/2005

Drug/Important Bio-Agent (IBA)

1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2013
1	Epithelial Cell Adhesion MoleculeIBA 01/2013
1	Biological ProductsIBA 01/2013
1	CreatinineIBA 01/2013
1	tucotuzumab celmoleukinIBA 01/2013

Therapy/Procedure

3	Transplantation 06/2006 - 02/2005
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 06/2006 - 02/2005
1	Therapeutics 06/2006